Peer Exchange

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Role of a Specialist Versus PCP in Multiple Sclerosis
October 03, 2019 – 
Perspectives on the respective roles of a primary care physician (PCP) versus a specialist when identifying and managing multiple sclerosis.
Hydroxyurea's Role in Managing Sickle Cell Disease
October 01, 2019 – 
Moving on to treatment strategies, the panel reviews hydroxyurea’s role as mainstay therapy for sickle cell disease.
Sickle Cell Disease: Treatment Goals and Guidelines
October 01, 2019 – 
Key opinion leaders provide perspective on the goals of therapy when treating patients with sickle cell disease.
The Impact of OCM in the Treatment of Multiple Myeloma
September 27, 2019 – 
A review of the potential impact of the Oncology Care Model (OCM) on the treatment of multiple myeloma.
Entering a 4-Drug Regimen for Multiple Myeloma Treatment
September 27, 2019 – 
The panel discusses the future of 4-drug combinations for the treatment of multiple myeloma, including the GRIFFIN trial.
Discrepancy in Defining Secondary-Progressive Multiple Sclerosis
September 26, 2019 – 
The panel emphasizes challenges faced when attempting to identify secondary-progressive multiple sclerosis.
Understanding the Transition From RRMS to SPMS
September 26, 2019 – 
Experts provide insight on the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary-progressive multiple sclerosis (SPMS).
A Patient's Journey With Sickle Cell Disease
September 25, 2019 – 
Concluding its discussion on the nature and identification of sickle cell disease, the panel shares insight on the overarching patient journey.
Considering Complications of Sickle Cell Disease
September 25, 2019 – 
Experts address acute and chronic complications that occur as a result of sickle cell disease, shedding light on long-term costs.
MAIA Trial: Transplant-Ineligible Patients With MM
September 20, 2019 – 
Experts delve into evolving standards of care for patients who are not eligible for transplant in multiple myeloma treatment and discuss the outcomes of the MAIA trial.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.